Anika Therapeutics, Inc.

Equities

ANIK

US0352551081

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2026-03-06 pm EST			5-day change	1st Jan Change
14.12 ^USD	-0.91%		-1.67%	+46.93%

Feb. 27	Barrington Adjusts Price Target on Anika Therapeutics to $17 From $16, Maintains Outperform Rating	MT
Feb. 27	B. Riley Adjusts Price Target on Anika Therapeutics to $18 From $16, Maintains Buy Rating	MT

Tranche Update on Anika Therapeutics, Inc.'s Equity Buyback Plan announced on May 28, 2024.

Published on 07/30/2025 at 04:12 pm EDT

S&P Capital IQ

ANIKA THERAPEUTICS, INC.

-0.91%

From April 1, 2025 to June 30, 2025, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 746,431 shares, representing 5.1% for $15.39 million under the buyback announced on May 28, 2024.

Latest news about Anika Therapeutics, Inc.

Feb. 27	Barrington Adjusts Price Target on Anika Therapeutics to $17 From $16, Maintains Outperform Rating	MT
Feb. 27	B. Riley Adjusts Price Target on Anika Therapeutics to $18 From $16, Maintains Buy Rating	MT
Feb. 26	Anika Therapeutics, Inc., Q4 2025 Earnings Call, Feb 26, 2026
Feb. 26	Anika Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
Feb. 26	Anika Therapeutics, Inc. Provides Earnings Guidance for the Full Year 2026	CI
Jan. 08	Anika Therapeutics Appoints CFO Stephen Griffin as Chief Executive Officer	MT
Jan. 08	Anika Therapeutics, Inc. Announces Executive Changes	CI
Jan. 08	Anika Therapeutics, Inc. Announces Chief Executive Officer Changes	CI
Nov. 05	Tranche Update on Anika Therapeutics, Inc.'s Equity Buyback Plan announced on May 28, 2024.	CI
Nov. 05	Anika Therapeutics, Inc., Q3 2025 Earnings Call, Nov 05, 2025
Nov. 05	Anika Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
Nov. 05	Anika beats Q3 revenue estimates, maintains guidance	RE
Nov. 05	Anika Therapeutics, Inc. Confirms Earnings Guidance for the Full Year 2025	CI
Nov. 05	Anika Therapeutics Reports Filing of Final PMA Module for Hyalofast Cartilage Repair Scaffold and Data from U.S. Pivotal Fasttrack Phase III Study	CI
25-07-30	Tranche Update on Anika Therapeutics, Inc.'s Equity Buyback Plan announced on May 28, 2024.	CI

Chart Anika Therapeutics, Inc.

Duration

Period

ANIK: Dynamic Chart

Company Profile

Anika Therapeutics, Inc. is a global joint preservation company. The Company creates and delivers advancements in early intervention orthopedic care, including in the areas of osteoarthritis (OA) pain management, regenerative solutions, and sports medicine. It is focused on developing, manufacturing and commercializing products on its hyaluronic acid (HA), technology platform. Its OA Pain Management product family consists of Monovisc and Orthovisc, its injectable, HA, OA Pain Management offerings are indicated to provide pain relief from osteoarthritis conditions; and Cingal, its novel, next generation, single-injection OA Pain Management product consisting of its proprietary cross-linked HA material combined with a steroid. Its Joint Preservation and Restoration product family consists of its portfolio of orthopedic regenerative solutions products utilizing HA, including Integrity, its new hyaluronic acid-based scaffold for rotator cuff and other tendon repairs.

Employees

235

Sector

Medical Equipment, Supplies & Distribution

More about the company